Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Malaysia ETF (EWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Malaysia ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI Malaysia ETF trades at $27.25. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EWM | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $30.42 |
52-Week Low | $4.17 | $23.49 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWM, the iShares MSCI Malaysia ETF, trades at $27.24, up 1.0% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF is heavily weighted in Financials (54%) and Industrials (21%), positioning it to benefit from Malaysia's data center expansion and tourism initiatives. A dividend of $0.57 is scheduled for payment on June 18, 2026.
Outlook is mixed: growth potential exists from Malaysia's economic initiatives, but bearish technicals and regional geopolitical risks from Middle East conflicts pose headwinds. Investors should weigh exposure to emerging market volatility against sector-specific opportunities in semiconductors and energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →
